The company is acquiring the Europe based Cenexi group, whose profit margins and return ratios are much lower than Gland Pharma's
CNBC-TV18‘s Kritika Saxena caught up with R Srikrishna, CEO, Hexaware on the sidelines of the NASSCOM Leadership Forum. Srikrishna is confident of outperforming the industry growth.